Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
9 "Imatinib"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Sarcoma
Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study
Joonha Kwon, Jun Hyeong Lee, Young Han Lee, Jeeyun Lee, Jin-Hee Ahn, Se Hyun Kim, Seung Hyun Kim, Tae Il Kim, Kum-Hee Yun, Young Suk Park, Jeong Eun Kim, Kyu Sang Lee, Jung Kyoon Choi, Hyo Song Kim
Cancer Res Treat. 2022;54(4):1240-1255.   Published online January 17, 2022
DOI: https://doi.org/10.4143/crt.2021.1194
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Desmoid tumor, also known as aggressive fibromatosis, is well-characterized by abnormal Wnt/β-catenin signaling. Various therapeutic options, including imatinib, are available to treat desmoid tumor. However, the molecular mechanism of why imatinib works remains unclear. Here, we describe potential roles of NOTCH2 and HES1 in clinical response to imatinib at genome and transcriptome levels.
Materials and Methods
We identified somatic mutations in coding and noncoding regions via whole-genome sequencing. To validate the genetic interaction with expression level in desmoid-tumor condition, we utilized large-scale whole-genome sequencing and transcriptome datasets from the Pan-Cancer Analysis of Whole Genomes project. RNA-sequencing was performed using prospective and retrospective cohort samples to evaluate the expressional relevance with clinical response.
Results
Among 20 patients, four (20%) had a partial response and 14 (66.7%) had stable disease, 11 of which continued for ≥ 1 year. With gene-wise functional analyses, we detected a significant correlation between recurrent NOTCH2 noncoding mutations and clinical response to imatinib. Based on Pan-Cancer Analysis of Whole Genomes data analyses, NOTCH2 mutations affect expression levels particularly in the presence of CTNNB1 missense mutations. By analyzing RNA-sequencing with additional desmoid tumor samples, we found that NOTCH2 expression was significantly correlated with HES1 expression. Interestingly, NOTCH2 had no statistical power to discriminate between responders and non-responders. Instead, HES1 was differentially expressed with statistical significance between responders and non-responders.
Conclusion
Imatinib was effective and well tolerated for advanced desmoid tumor treatment. Our results show that HES1, regulated by NOTCH2, as an indicator of sensitivity to imatinib, and an important therapeutic consideration for desmoid tumor.

Citations

Citations to this article as recorded by  
  • The Notch signaling pathway in desmoid tumor: Recent advances and the therapeutic prospects
    Chuanxi Zheng, Jianghong Huang, Gang Xu, Wei Li, Xin Weng, Shiquan Zhang
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2024; 1870(1): 166907.     CrossRef
  • Long‐term result of 125I seed brachytherapy for pediatric desmoid tumor in the head and neck
    Yi‐Wei Zhong, Xiao‐Ming Lyu, Yan Shi, Chuan‐Bin Guo, Jian‐Guo Zhang, Lei Zheng
    Pediatric Blood & Cancer.2023;[Epub]     CrossRef
  • Update on Familial Adenomatous Polyposis-Associated Desmoid Tumors
    Wanjun Yang, Pei-Rong Ding
    Clinics in Colon and Rectal Surgery.2023; 36(06): 400.     CrossRef
  • Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams
    Igino Simonetti, Federico Bruno, Roberta Fusco, Carmen Cutolo, Sergio Venanzio Setola, Renato Patrone, Carlo Masciocchi, Pierpaolo Palumbo, Francesco Arrigoni, Carmine Picone, Andrea Belli, Roberta Grassi, Francesca Grassi, Antonio Barile, Francesco Izzo,
    Journal of Personalized Medicine.2022; 12(7): 1153.     CrossRef
  • 6,766 View
  • 272 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Gastrointestinal cancer
Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis
Sora Kang, Min-Hee Ryu, Yeong Hak Bang, Hyung-Don Kim, Hyung Eun Lee, Yoon-Koo Kang
Cancer Res Treat. 2022;54(4):1167-1174.   Published online December 6, 2021
DOI: https://doi.org/10.4143/crt.2021.1040
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Three years of adjuvant imatinib is the standard treatment for resected gastrointestinal stromal tumors (GISTs) with rupture, but the recurrence rate is prominently high. We aimed to investigate the efficacy and safety of 5-year adjuvant imatinib compared with 3-year treatment in patients with a ruptured GIST following surgical resection.
Materials and Methods
A total of 51 patients were included in the analysis. The assessment of GIST rupture was based on Nishida’s classification. Twenty patients who were diagnosed before November 2013 were treated with 5 years of imatinib, and 31 patients who were diagnosed after November 2013 were treated with 3 years of imatinib. We retrospectively compared the clinical outcomes of the two groups.
Results
Baseline characteristics and the incidence of the adverse events were generally comparable between the two groups. During a median follow-up duration of 43.8 months and 104.2 months in the 3- and 5-year group, 8 and 9 patients had a disease recurrence, respectively. The 5-year group showed better recurrence-free survival (RFS) than the 3-year group. In multivariate analysis, low mitotic index was a significant independent favorable prognostic factor for RFS, while 5-year imatinib treatment was marginally associated with a favorable RFS.
Conclusion
Five years of adjuvant imatinib treatment in patients with ruptured GIST was associated with favorable survival outcomes with manageable toxicity profiles. Our findings warrant validation and confirmation in future studies.

Citations

Citations to this article as recorded by  
  • Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial
    Heikki Joensuu, Annette Reichardt, Mikael Eriksson, Peter Hohenberger, Kjetil Boye, Silke Cameron, Lars H. Lindner, Philipp J. Jost, Sebastian Bauer, Jochen Schütte, Stefan Lindskog, Raija Kallio, Panu M. Jaakkola, Dorota Goplen, Eva Wardelmann, Peter Rei
    British Journal of Cancer.2024; 131(2): 299.     CrossRef
  • Two Decades of Gastrointestinal Stromal Tumor Management With First-Line Treatment: A Case Report
    Maria M Pereira, Elisabete Couto, Ali Shamseddine, Teresa Macedo
    Cureus.2024;[Epub]     CrossRef
  • Imatinib

    Reactions Weekly.2023; 1960(1): 224.     CrossRef
  • Clinical importance of tumor rupture in gastrointestinal stromal tumor
    Toshirou Nishida, Naoto Gotouda, Tsuyoshi Takahashi, Hui Cao
    Journal of Digestive Diseases.2023;[Epub]     CrossRef
  • Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours
    Marin Golčić, Robin L. Jones, Paul Huang, Andrea Napolitano
    Cancers.2023; 15(16): 4081.     CrossRef
  • Impact of tumour rupture risk on the oncological rationale for the surgical treatment choice of gastrointestinal stromal tumours
    Nadia Peparini
    World Journal of Gastrointestinal Surgery.2023; 15(8): 1559.     CrossRef
  • Clinical outcomes and prognostic factors for patients with high‐risk gastrointestinal stromal tumors treated with 3‐year adjuvant imatinib
    Yeong Hak Bang, Min‐Hee Ryu, Hyung‐Don Kim, Hyung Eun Lee, Yoon‐Koo Kang
    International Journal of Cancer.2022; 151(10): 1770.     CrossRef
  • Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features
    Fu-Hai Wang, Hua-Long Zheng, Jin-Tao Li, Ping Li, Chao-Hui Zheng, Qi-Yue Chen, Chang-Ming Huang, Jian-Wei Xie
    La radiologia medica.2022; 127(10): 1085.     CrossRef
  • Development and validation of a prognostic model to predict the prognosis of patients with colorectal gastrointestinal stromal tumor: A large international population-based cohort study
    Yiding Li, Yujie Zhang, Yang Fu, Wanli Yang, Xiaoqian Wang, Lili Duan, Liaoran Niu, Junfeng Chen, Wei Zhou, Jinqiang Liu, Jing Wang, Daiming Fan, Liu Hong
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 5,249 View
  • 201 Download
  • 5 Web of Science
  • 9 Crossref
Close layer
Case Report
Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia
Xiaoyu Xu, Qiongyu Lu, Zheng Wang, Ping Cai, Zhao Zeng, Ling Zhang, Man Wang, Liang Ma, Changgeng Ruan, Suning Chen
Cancer Res Treat. 2021;53(3):889-892.   Published online December 24, 2020
DOI: https://doi.org/10.4143/crt.2020.1272
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Platelet-derived growth factor receptor beta (PDGFRB) rearrangements play an important role in the pathogenesis of eosinophilia-associated myeloid/lymphoid neoplasms. Up to now, more than 70 PDGFRB fusions have been identified. Here, a novel PDGFRB fusion gene CSNK2A1-PDGFRB has been identified in myeloproliferative neoplasm (MPN) with eosinophilia by RNA-sequencing, which has been verified by reverse transcription polymerase chain reaction and Sanger sequencing. The new PDGFRB fusion partner gene CSNK2A1 encoded one of the two catalytic subunit of casein kinase II (CK2). To our knowledge, this is the first report on the involvement of CSNK2A1 in fusion genes, especially fusion with another kinase PDGFRB in MPN. In addition, the CSNK2A1-PDGFRB fusion retained the entire kinase domain of PDGFRB and response to imatinib at low concentration. The patient with CSNK2A1-PDGFRB was sensitive to imatinib treatment and acquired sustained complete remission.

Citations

Citations to this article as recorded by  
  • The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph‐like ALL
    Guo‐fa Xu, Zhao Zeng, Zhi‐bo Zhang, Xiao‐mei Zhang, Man Wang, Qing Xiao, Jun Li, Xiao‐qing Xie, Sanxiu He, Hui‐hui Fu, Yi Liu, Zai‐liang Yang, Yu Chen, Jie Shi, Biao Wang, Hui‐ying Qiu, Qi Zhou, Yao Liu, Su‐ning Chen
    Journal of Cellular and Molecular Medicine.2024;[Epub]     CrossRef
  • Novel gene fusions in human oropharyngeal carcinoma
    Katsuhiro Masago, Hiroaki Kuroda, Eiichi Sasaki, Yasuko Fujita, Shiro Fujita, Yoshitsugu Horio, Motoyoshi Endo, Hiromasa Ishihara, Nobuhiro Hanai, Hirokazu Matsushita
    Cancer Genetics.2024; 286-287: 29.     CrossRef
  • Prednisone

    Reactions Weekly.2022; 1895(1): 329.     CrossRef
  • A novel WNK1::PDGFRB fusion gene in myeloid neoplasm with eosinophilia: a case report
    Tiantian Wang, Junjie Cao, Qingqing Lin, Xuhui Liu, Man Wang, Renzhi Pei, Ying Lu
    Annals of Hematology.2022; 101(10): 2359.     CrossRef
  • The Role of Protein Kinase CK2 in Development and Disease Progression: A Critical Review
    Daniel Halloran, Venu Pandit, Anja Nohe
    Journal of Developmental Biology.2022; 10(3): 31.     CrossRef
  • Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2
    Zaira Spinello, Anna Fregnani, Laura Quotti Tubi, Livio Trentin, Francesco Piazza, Sabrina Manni
    International Journal of Molecular Sciences.2021; 22(7): 3716.     CrossRef
  • Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
    Sareshma Sudhesh Dev, Syafiq Asnawi Zainal Abidin, Reyhaneh Farghadani, Iekhsan Othman, Rakesh Naidu
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • 5,377 View
  • 209 Download
  • 7 Crossref
Close layer
Original Articles
Factors Influencing Imatinib-Induced Hepatotoxicity
Ji Min Han, Jeong Yee, Yoon Sook Cho, Hye Sun Gwak
Cancer Res Treat. 2020;52(1):181-188.   Published online June 26, 2019
DOI: https://doi.org/10.4143/crt.2019.131
AbstractAbstract PDFPubReaderePub
Purpose
Although imatinib-induced hepatotoxicity may aggravate the patient’s clinical condition and alter the treatment plan, the underlying mechanism of and factors influencing imatinibinduced hepatotoxicity have rarely been investigated. The purpose of this study was to investigate factors affecting on the incidence of hepatotoxicity within 90 days after starting imatinib treatment and time to onset of imatinib-induced hepatotoxicity.
Materials and Methods
We retrospectively evaluated the records of 177 patients receiving imatinib from October 2012 to September 2017. The analyzed factors included sex, age, body weight, body surface area, underlying disease, and concomitant drugs.
Results
The proportion of patients with hepatotoxicity within 90 days after imatinib administration was 33.9%. Proton pump inhibitors (PPIs) increased the incidence of hepatotoxicity approximately 3.8-fold and doubled the hazard of time to reach hepatotoxicity. Patients with liver disease or hepatitis B virus (HBV) carriers had a more than 8-fold higher risk of hepatotoxicity and a 5.2-fold increased hazard of hepatotoxicity compared to those without liver disease or HBV. Patients with body weight under 55 kg had a 2.2-fold higher risk for occurrence of hepatotoxicity. Patients with an imatinib dose > 400 mg had a 2.3-fold increased hazard of time to reach hepatotoxicity compared to those with an imatinib dose ≤ 400 mg.
Conclusion
The findings of this study suggest that the use of PPIs and presence of liver disease or HBV were associated with imatinib-induced hepatotoxicity. Thus, close liver function monitoring is recommended, especially in patients with liver impairment or using PPIs.

Citations

Citations to this article as recorded by  
  • Efficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomes
    Rongrong Fu, Rui Chang, Andong Peng, Changshun Feng, Weifan Zhu, Yi Chen, Xue Tian, Rui Wang, Hui Yan, Dianlong Jia, Jun Li
    Pharmaceutical Development and Technology.2024; 29(1): 52.     CrossRef
  • The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review
    Mansour Tobaiqy, Nawal Helmi, Katie MacLure, Sylvia Saade
    International Journal of Clinical Pharmacy.2024; 46(2): 368.     CrossRef
  • Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis
    Emilia Neuwirt, Giovanni Magnani, Tamara Ćiković, Svenja Wöhrle, Larissa Fischer, Anna Kostina, Stephan Flemming, Nora J. Fischenich, Benedikt S. Saller, Oliver Gorka, Steffen Renner, Claudia Agarinis, Christian N. Parker, Andreas Boettcher, Christopher J
    Science Signaling.2023;[Epub]     CrossRef
  • NLRP3 and cancer: Pathogenesis and therapeutic opportunities
    Isak W. Tengesdal, Charles A. Dinarello, Carlo Marchetti
    Pharmacology & Therapeutics.2023; 251: 108545.     CrossRef
  • Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms
    Shubhrat Purwar, Anam Fatima, Himashree Bhattacharyya, Lakshmi Venkata Simhachalam Kutikuppala, Matei-Alexandru Cozma, Bahadar Singh Srichawla, Leah Komer, Khulud Mahmood Nurani, Mihnea-Alexandru Găman
    World Journal of Hepatology.2023; 15(9): 1021.     CrossRef
  • Imatinib-induced hepatotoxicity via oxidative stress and activation of NLRP3 inflammasome: an in vitro and in vivo study
    Feng-Ru Huang, Wen-Tong Fang, Zi-Ping Cheng, Ye Shen, Dun-Jian Wang, Yong-Qing Wang, Lu-Ning Sun
    Archives of Toxicology.2022; 96(4): 1075.     CrossRef
  • A Risk Scoring System Utilizing Machine Learning Methods for Hepatotoxicity Prediction One Year After the Initiation of Tyrosine Kinase Inhibitors
    Ji Min Han, Jeong Yee, Soyeon Cho, Min Kyoung Kim, Jin Young Moon, Dasom Jung, Jung Sun Kim, Hye Sun Gwak
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Drug‐Drug Interactions and Disease Status Are Associated With Irinotecan‐Induced Hepatotoxicity: A Cross‐Sectional Study in Shanghai
    Juan Li, Bing Chen, Wen‐qi Xi, Wan Jia, Wei‐xia Zhang, Xiao‐lan Bian
    The Journal of Clinical Pharmacology.2022; 62(9): 1160.     CrossRef
  • A new strategy for the rapid identification and validation of direct toxicity targets of psoralen-induced hepatotoxicity
    Sitong Sun, Manshu Wang, Yu Yuan, Shuo Wang, Haoran Ding, Chenrui Liang, Xiaomeng Li, Simiao Fan, Yubo Li
    Toxicology Letters.2022; 363: 11.     CrossRef
  • Effects of High-Dose of Copper Amino Acid Complex on Laying Performance, Hematological and Biochemical Parameters, Organ Index, and Histopathology in Laying Hens
    Qin Zhou, Jiaming Zhu, Bing Liu, Jialing Qiu, Xintao Lu, Brian Curtin, Fei Ji, Dongyou Yu
    Biological Trace Element Research.2021; 199(8): 3045.     CrossRef
  • Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile
    Debasish Basak, Scott Arrighi, Yasenya Darwiche, Subrata Deb
    Life.2021; 12(1): 48.     CrossRef
  • Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study
    Ji Min Han, Hye Won Han, Jeong Yee, Min Kyoung Kim, Jin Young Moon, Soyeon Cho, Dasom Jung, Yoon Sook Cho, Inyoung Seo, Jae Youn Kim, Hye Sun Gwak
    European Journal of Clinical Pharmacology.2020; 76(8): 1183.     CrossRef
  • 7,009 View
  • 226 Download
  • 14 Web of Science
  • 12 Crossref
Close layer
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
Myoung Kyun Son, Min-Hee Ryu, Joon Oh Park, Seock-Ah Im, Tae-Yong Kim, Su Jin Lee, Baek-Yeol Ryoo, Sook Ryun Park, Yoon-Koo Kang
Cancer Res Treat. 2017;49(2):350-357.   Published online July 19, 2016
DOI: https://doi.org/10.4143/crt.2016.067
AbstractAbstract PDFPubReaderePub
Purpose
The aim of this study was to confirm the efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors (GISTs) reported in the GRID phase III trial in Korean patients.
Materials and Methods
Fifty-seven Korean patientswith advanced GISTwho experienced both imatinib and sunitinib failure were enrolled in the management access program between December 2012 and November 2013 and treated with regorafenib (160 mg orally once daily in a 3 weeks on /1 week off).
Results
None of the patients achieved a complete or partial response while 25 patients (44%) showed stable disease for ≥ 12 weeks. With a median follow-up of 12.7 months (range, 0.2 to 27.6 months), the median progression-free survival and overall survival were 4.5 months (95% confidence interval [CI], 3.8 to 5.3) and 12.9 months (95% CI, 8.1 to 17.7), respectively. Interestingly, 15 patients (26%) experienced an exacerbation of their cancer-related symptoms (abdominal pain in eight and abdominal distension in five) during the rest period for regorafenib, but all were ameliorated upon the resumption of regorafenib. The most common grade 3 or 4 adverse event was a hand-foot skin reaction (25%). The regorafenib dose was reduced in 44 patients (77%) due to toxicity, which manifested mainly as a handfoot skin reaction (n=31).
Conclusion
This study confirmed the efficacy and safety of regorafenib for advanced GIST after imatinib and sunitinib failure in Korean patients. Considering the exacerbation of the cancer-related symptoms observed during the rest periods, further exploration of the continuous dosing schedule of regorafenib is warranted in future clinical trials.

Citations

Citations to this article as recorded by  
  • English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology
    Seiichi Hirota, Ukihide Tateishi, Yuji Nakamoto, Hidetaka Yamamoto, Shinji Sakurai, Hirotoshi Kikuchi, Tatsuo Kanda, Yukinori Kurokawa, Haruhiko Cho, Toshirou Nishida, Akira Sawaki, Masato Ozaka, Yoshito Komatsu, Yoichi Naito, Yoshitaka Honma, Fumiaki Tak
    International Journal of Clinical Oncology.2024; 29(6): 647.     CrossRef
  • A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours
    Hyung-Don Kim, Changhoon Yoo, Min-Hee Ryu, Yoon-Koo Kang
    British Journal of Cancer.2023; 129(2): 275.     CrossRef
  • Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
    Maria Susanna Grimaudo, Alice Laffi, Nicolò Gennaro, Roberta Fazio, Federico D’Orazio, Laura Samà, Licia Vanessa Siracusano, Federico Sicoli, Salvatore Lorenzo Renne, Armando Santoro, Alexia Francesca Bertuzzi
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours
    Marin Golčić, Robin L. Jones, Paul Huang, Andrea Napolitano
    Cancers.2023; 15(16): 4081.     CrossRef
  • Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) – A systematic review
    Charlotte Margareta Brinch, Ninna Aggerholm-Pedersen, Estrid Hogdall, Anders Krarup-Hansen
    Critical Reviews in Oncology/Hematology.2022; 172: 103650.     CrossRef
  • Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature
    Deborah van de Wal, Mai Elie, Axel Le Cesne, Elena Fumagalli, Dide den Hollander, Robin L. Jones, Gloria Marquina, Neeltje Steeghs, Winette T. A. van der Graaf, Olga Husson
    Cancers.2022; 14(7): 1832.     CrossRef
  • Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors
    Ryugo Teranishi, Tsuyoshi Takahashi, Toshirou Nishida, Seiichi Hirota, Yukinori Kurokawa, Takuro Saito, Kazuyoshi Yamamoto, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Masaaki Motoori, Takeshi Omori, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki
    International Journal of Clinical Oncology.2022; 27(7): 1164.     CrossRef
  • The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review
    Vahe Khachatryan, Asmaa Muazzam, Chandani Hamal, Lakshmi Sai Deepak Reddy Velugoti, Godfrey Tabowei, Greeshma N Gaddipati, Maria Mukhtar, Mohammed J Alzubaidee, Raga Sruthi Dwarampudi, Sheena Mathew, Sumahitha Bichenapally, Lubna Mohammed
    Cureus.2022;[Epub]     CrossRef
  • CT Image Examination Based on Virtual Reality Analysis in Clinical Diagnosis of Gastrointestinal Stromal Tumors
    Zhiying Wang, Qiaoyan Qu, Ke Cai, Ting Xu, Zhihan Lv
    Journal of Healthcare Engineering.2021; 2021: 1.     CrossRef
  • The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
    Agnieszka Kaczmarska, Patrycja Śliwa, Monika Lejman, Joanna Zawitkowska
    International Journal of Molecular Sciences.2021; 22(21): 12089.     CrossRef
  • Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors
    Seketoulie Keretsu, Suparna Ghosh, Seung Joo Cho
    International Journal of Molecular Sciences.2020; 21(21): 8232.     CrossRef
  • Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non‑randomized, single‑center study
    Chia‑Hsiang Hu, Chun‑Nan Yeh, Jen‑Shi Chen, Chun‑Yi Tsai, Shang‑Yu Wang, Chi‑Tung Cheng, Ta‑Sen Yeh
    Oncology Letters.2020; 20(3): 2131.     CrossRef
  • Meta-Analysis of Regorafenib-Associated Adverse Events and Their Management in Colorectal and Gastrointestinal Stromal Cancers
    Ganfeng Xie, Yuzhu Gong, Shuang Wu, Chong Li, Songtao Yu, Zhe Wang, Jianfang Chen, Quanfeng Zhao, Jianjun Li, Houjie Liang
    Advances in Therapy.2019; 36(8): 1986.     CrossRef
  • Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib
    Jae-Joon Kim, Min-Hee Ryu, Changhoon Yoo, Mo Youl Beck, Jung Eun Ma, Yoon-Koo Kang
    The Oncologist.2019; 24(11): e1212.     CrossRef
  • Growing Role of Regorafenib in the Treatment of Patients with Sarcoma
    Mark Agulnik, Steven Attia
    Targeted Oncology.2018; 13(4): 417.     CrossRef
  • Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients
    Gustavo Schvartsman, Michael J. Wagner, Behrang Amini, Chrystia M. Zobniw, Van Anh Trinh, Andrea G. Barbo, Heather Y. Lin, Wei-Lien Wang, Anthony Paul Conley, Vinod Ravi, Dejka M. Araujo, Maria Alejandra Zarzour, Robert S. Benjamin, Shreyaskumar Patel, Ne
    Scientific Reports.2017;[Epub]     CrossRef
  • Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib
    Bin Zhao, Hong Zhao
    Oncotarget.2017; 8(55): 93813.     CrossRef
  • 10,241 View
  • 371 Download
  • 22 Web of Science
  • 17 Crossref
Close layer
Special Article
Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, Han-Kwang Yang, Akira Sawaki, Seiichi Hirota, Jie Zheng, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Toshirou Nishida, Lin Shen, Li-Tzong Chen, Yoon-Koo Kang
Cancer Res Treat. 2016;48(4):1155-1166.   Published online June 24, 2016
DOI: https://doi.org/10.4143/crt.2016.187
AbstractAbstract PDFPubReaderePub
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors originating in the gastrointestinal tract. With the introduction of molecular-targeted therapy for GISTs which has yielded remarkable outcomes, these tumors have become a model of multidisciplinary oncological treatment. Although Western clinical guidelines are available for GISTs, such as those published by the National Comprehensive Cancer Network (NCCN) and the European Society of Medical Oncology (ESMO), the clinical situations in Asian countries are different from those in Western countries in terms of diagnostic methods, surgical approach, and availability of new targeted agents. Accordingly, we have reviewed current versions of several GIST guidelines published by Asian countries (Japan, Korea, China, and Taiwan) and the NCCN and ESMO and discussed the areas of dissensus. We here present the first version of the Asian GIST consensus guidelines that were prepared through a series of meetings involving multidisciplinary experts in the four countries. These guidelines provide an optimal approach to the diagnosis and management of GIST patients in Asian countries.

Citations

Citations to this article as recorded by  
  • Clinical importance of tumor rupture in gastrointestinal stromal tumor
    Toshirou Nishida, Naoto Gotouda, Tsuyoshi Takahashi, Hui Cao
    Journal of Digestive Diseases.2024; 25(9-10): 542.     CrossRef
  • Gastric gastrointestinal stromal tumors: therapeutic strategies and long-term prognosis
    Chunhui Shou, Zhou Chen, Zhijian Li, Weili Yang, Qing Zhang, Hao Bai, Jiren Yu
    Scandinavian Journal of Gastroenterology.2024; 59(2): 239.     CrossRef
  • Pimitespib for the Treatment of Advanced Gastrointestinal Stromal tumors and Other Tumors
    Toshihiko Doi, Noboru Yamamoto, Shuichi Ohkubo
    Future Oncology.2024; 20(9): 507.     CrossRef
  • Endoscopic resection for the treatment of gastric gastrointestinal stromal tumors: a retrospective study from a large tertiary hospital in China
    Zhengting He, Chen Du, Bingqian Cheng, Jiancong Feng, Nanjun Wang, Yan Ma, Longsong Li, Bo Zhang, Hongbin Wang, Ping Tang, Ningli Chai, Enqiang Linghu
    Surgical Endoscopy.2024; 38(3): 1398.     CrossRef
  • Comparative Analysis of Enbloc or Piecemeal Removal After Enbloc Resection of Gastrointestinal Stromal Tumors
    Jing-wen Zhang, Chang-qing Guo, Shan-shan Zhu, Ghulam Nabi, Nan Dai, Xiao-yu Wan, Ping Liu, Fang-bin Zhang, Yang Fu, Xin-gung Cao
    Digestive Diseases and Sciences.2024; 69(5): 1755.     CrossRef
  • Automatically optimized radiomics modeling system for small gastric submucosal tumor (<2 cm) discrimination based on EUS images
    Mingyan Cai, Baohui Song, Yinhui Deng, Pingting Gao, Shilun Cai, Ayimukedisi Yalikong, Enpan Xu, Yunshi Zhong, Jinhua Yu, Pinghong Zhou
    Gastrointestinal Endoscopy.2024; 99(4): 537.     CrossRef
  • English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology
    Seiichi Hirota, Ukihide Tateishi, Yuji Nakamoto, Hidetaka Yamamoto, Shinji Sakurai, Hirotoshi Kikuchi, Tatsuo Kanda, Yukinori Kurokawa, Haruhiko Cho, Toshirou Nishida, Akira Sawaki, Masato Ozaka, Yoshito Komatsu, Yoichi Naito, Yoshitaka Honma, Fumiaki Tak
    International Journal of Clinical Oncology.2024; 29(6): 647.     CrossRef
  • Efficacy and Safety of Endoscopic Resection for Gastric Gastrointestinal Stromal Tumors Originating from the Muscularis Propria
    Ji Li, Dong Xu, Wei-Feng Huang, Shao-Kun Hong, Jin-Yan Zhang
    Digestive Diseases and Sciences.2024; 69(6): 2184.     CrossRef
  • Clinical outcomes of endoscopic resection for the treatment of intermediate- or high-risk gastric small gastrointestinal stromal tumors: a multicenter retrospective study
    Enpan Xu, Qiang Shi, Zhipeng Qi, Bing Li, Huihui Sun, Zhong Ren, Shilun Cai, Dongli He, Zhengtao Lv, Zhanghan Chen, Liang Zhong, Leiming Xu, Xiaobo Li, Shuchang Xu, Pinghong Zhou, Yunshi Zhong
    Surgical Endoscopy.2024; 38(6): 3353.     CrossRef
  • Current trends in the management of Gastro-oEsophageal cancers: Updates to the ESSO core curriculum (ESSO-ETC-UGI-WG initiative)
    Johnn Henry Herrera Kok, Luigi Marano, Jan Willem van den Berg, Preethi Shetty, Yogesh Vashist, Laura Lorenzon, Beate Rau, Richard van Hillegersberg, Giovanni de Manzoni, Andrea Spallanzani, Won Jun Seo, Hiromi Nagata, Clarisse Eveno, Stefan Mönig, Karen
    European Journal of Surgical Oncology.2024; 50(7): 108387.     CrossRef
  • Efficacy of real-time artificial intelligence-aid endoscopic ultrasonography diagnostic system in discriminating gastrointestinal stromal tumors and leiomyomas: a multicenter diagnostic study
    Zhixia Dong, Xiangyun Zhao, Hangbin Zheng, HanYao Zheng, Dafan Chen, Jia Cao, Zili Xiao, Yunwei Sun, Qian Zhuang, Shan Wu, Jie Xia, Min Ning, Binjie Qin, Hui Zhou, Jinsong Bao, Xinjian Wan
    eClinicalMedicine.2024; 73: 102656.     CrossRef
  • Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors
    Hyung-Don Kim, Min-Hee Ryu, Young Soo Park, Changhoon Yoo, Sung-Joo Kim, Yoon-Koo Kang
    Clinical Cancer Research.2024; 30(13): 2743.     CrossRef
  • Optimal management options for esophageal gastrointestinal stromal tumors (E-GIST)
    Shanshan Zhu, Changqing Guo, Jingwen Zhang, Nan Dai, Saif Ullah, Ping Liu, Yang Fu, Ge Zhang, Fangbin Zhang, Shengang Zhang, Xinguang Cao
    European Journal of Surgical Oncology.2024; 50(9): 108527.     CrossRef
  • Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors
    Tadayoshi Hashimoto, Yoshiaki Nakamura, Yoshito Komatsu, Satoshi Yuki, Naoki Takahashi, Naohiro Okano, Hidekazu Hirano, Koushiro Ohtsubo, Takashi Ohta, Eiji Oki, Tomohiro Nishina, Hisateru Yasui, Hisato Kawakami, Taito Esaki, Nozomu Machida, Ayako Doi, Sh
    BJC Reports.2024;[Epub]     CrossRef
  • Impact of systemic steroids on the efficacy of first line imatinib treatment of patients with advanced gastrointestinal stromal tumors (GISTs)
    Sejin Kim, Hyung-Don Kim, Eo Jin Kim, Min-Hee Ryu, Yoon-Koo Kang
    BMC Cancer.2024;[Epub]     CrossRef
  • Unraveling Gastric and Small Intestine Gastrointestinal Stromal Tumors: A Review of Our Current Knowledge
    Panagiotis Eskitzis, Vasiliki Michou, Rodoula Theoti, Antonia Antoniou, Drosos Tsavlis, Doxakis Anestakis
    Gastrointestinal Disorders.2024; 6(4): 842.     CrossRef
  • Mean platelet volume/platelet count ratio can predict the recurrence-free survival rate of patients after complete resection of gastrointestinal stromal tumors
    Xinlian Du, Xinxin Zang, Hanbo Zhang, Lijia Liu, Ying Xu, Xuedong Li, Ruishu Mou, Haitao Xu, Jiuxin Zhu, Rui Xie
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Genotypical analysis of gastrointestinal stromal tumors using next-generation sequencing
    Trupti V. Deshpande, Pranav Dorwal, Akshay A Anikhindi, Nishant Tiwari, Dharmendar Jain, Simmi Mehra, Ashok Vaid, Vimarsh Raina
    Indian Journal of Cancer.2024; 61(3): 477.     CrossRef
  • Diagnostic and Therapeutic Challenges in the Management of Acute Massive Overt Bleeding of Jejunal Gastrointestinal Stromal Tumours: Case Series
    Satish Subbiah Nagaraj, Sriram Deivasigamani, Amresh Aruni, Hemanth Kumar, Anurag Sachan, Jayanta Samanta, Amanjit Bal
    Journal of Gastrointestinal Cancer.2023; 54(1): 316.     CrossRef
  • Splenic capsulitis associated with gastric GIST
    Soumya Hariswamy, Sam Alhayo, Yasser Farooque
    ANZ Journal of Surgery.2023; 93(4): 1104.     CrossRef
  • Counting mitoses in gastrointestinal stromal tumours (GISTs): variable practices in the real-world setting and their clinical implications
    Michela Campora, Michele Paudice, Alessandro Gambella, Danila Comandini, Paola Parente, Marta Sbaraglia, Angelo Paolo Dei Tos, Federica Grillo, Luca Mastracci
    Virchows Archiv.2023; 482(3): 589.     CrossRef
  • Pure endoscopic resection versus laparoscopic assisted procedure for upper gastrointestinal stromal tumors: Perspective from a surgical endoscopist
    Hon Chi Yip, Jun Liang Teh, Anthony Y. B. Teoh, Philip Chiu
    Digestive Endoscopy.2023; 35(2): 184.     CrossRef
  • Gastrointestinal stromal tumor of jejunum misdiagnosed as uterine leiomyoma: A case report
    Min Yu, Miaomiao Sun, Shanwei Guo, Fangfang Nan
    Asian Journal of Surgery.2023; 46(3): 1457.     CrossRef
  • A Rare Gastric Subepithelial Lesion Removed through Submucosal Tunneling Endoscopic Resection: Case Report and Literature Review
    Mu-Ming Chien, Yun-Ho Lin, Chun-Chao Chang, Hsi-Yuan Chien
    Life.2023; 13(1): 179.     CrossRef
  • Clinical Efficacy and Safety of Endoscopic Treatment of Gastrointestinal Stromal Tumors in the Stomach
    Moon Kyung Joo, Jong-Jae Park, Yeon Ho Lee, Beom Jae Lee, Seong Min Kim, Won Shik Kim, Ah Young Yoo, Hoon Jai Chun, Sang Woo Lee
    Gut and Liver.2023; 17(2): 217.     CrossRef
  • Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours
    Yoichi Naito, Toshirou Nishida, Toshihiko Doi
    Gastric Cancer.2023; 26(3): 339.     CrossRef
  • Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions
    Yoon-Koo Kang, Hyung-Don Kim, Hyun Jin Kim, Young Soo Park, Mo-Youl Beck, Min-Hee Ryu
    Gastric Cancer.2023; 26(4): 604.     CrossRef
  • Risk factors of perforation in gastric stromal tumors during endoscopic resection: a retrospective case–control study
    Muhan Ni, Dehua Tang, Wei Ren, Rui Meng, Jinping Yang, Peng Yan, Xiwei Ding, Guifang Xu, Ying Lv, Min Chen, Hua Yang, Lei Wang
    Gastric Cancer.2023; 26(4): 590.     CrossRef
  • Clinical outcomes of endoscopic resection for the treatment of esophageal gastrointestinal stromal tumors: a ten-year experience from a large tertiary center in China
    Jia-Xin Xu, Tian-Yin Chen, Yan-Bo Liu, Xiao-Yue Xu, Wei-Feng Chen, Quan-Lin Li, Jian-Wei Hu, Wen-Zheng Qin, Ming-Yan Cai, Yi-Qun Zhang, Ping-Hong Zhou
    Surgical Endoscopy.2023; 37(8): 5883.     CrossRef
  • Efficacy of post‐first‐line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta‐analysis
    Kehan Hu, Hu Zhang, Mingrong Shu, Xingyue Wang
    Cancer Medicine.2023; 12(11): 12187.     CrossRef
  • A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours
    Hyung-Don Kim, Changhoon Yoo, Min-Hee Ryu, Yoon-Koo Kang
    British Journal of Cancer.2023; 129(2): 275.     CrossRef
  • Endoscopic resection for the treatment of non-gastric gastrointestinal stromal tumors: A retrospective study from a large tertiary hospital in China
    Chen Du, Zhengting He, Longsong Li, Bo Ning, Bo Zhang, Yaqi Zhai, Yan Ma, Ke Han, Hongbin Wang, Ping Tang, Ningli Chai, Enqiang Linghu
    Clinics and Research in Hepatology and Gastroenterology.2023; 47(7): 102152.     CrossRef
  • Gastrointestinal Stromal Tumor of Small Intestine
    Hyo Yeop Song, Geom Seog Seo, Hoon Gil Jo
    The Korean Journal of Gastroenterology.2023; 81(6): 276.     CrossRef
  • Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach
    Seong-Ho Kong, Yukinori Kurokawa, Jeong-Hwan Yook, Haruhiko Cho, Oh-Kyoung Kwon, Toru Masuzawa, Kyung Hee Lee, Sohei Matsumoto, Young Soo Park, Hiroshi Honda, Seung-Wan Ryu, Takashi Ishikawa, Hye Jin Kang, Kazuhito Nabeshima, Seock-Ah Im, Toshio Shimokawa
    Gastric Cancer.2023; 26(5): 775.     CrossRef
  • Non-exposed endoscopic wall-inversion surgery with one-step nucleic acid amplification for early gastrointestinal tumors: Personal experience and literature review
    Francesco Crafa, Serafino Vanella, Aristide Morante, Onofrio A Catalano, Kelsey L Pomykala, Mario Baiamonte, Maria Godas, Alexandra Antunes, Joaquim Costa Pereira, Valentina Giaccaglia
    World Journal of Gastroenterology.2023; 29(24): 3883.     CrossRef
  • Transgastric endoscopic ultrasound‐guided fine needle biopsy for diagnosing gastrointestinal stromal tumor of the jejunum
    Yuichi Takano, Fumitaka Niiya, Masatsugu Nagahama
    Digestive Endoscopy.2023;[Epub]     CrossRef
  • Simple Scoring Model Based on Enhanced CT in Preoperative Prediction of Biological Risk of Gastrointestinal Stromal Tumor
    Yating Wang, Genji Bai, Hui Zhang, Wei Chen
    Technology in Cancer Research & Treatment.2023;[Epub]     CrossRef
  • Goldilocks principle of minimally invasive surgery for gastric subepithelial tumors
    Wei-Jung Chang, Lien-Cheng Tsao, Hsu-Heng Yen, Chia-Wei Yang, Hung-Chi Chang, Chew-Teng Kor, Szu-Chia Wu, Kuo-Hua Lin
    World Journal of Gastrointestinal Surgery.2023; 15(8): 1629.     CrossRef
  • Comparison of Safety and Outcomes between Endoscopic and Surgical Resections of Intermediate-Risk Primary Gastric Gastrointestinal Stromal Tumors
    Ximei Ren, Muhan Ni, Tingting Zhu, Jinping Yang, Jinyan Liu, Shahzeb Hassan, Xiaoping Zou, Guifang Xu, Lei Wang
    Digestive Diseases.2023; 41(2): 187.     CrossRef
  • A giant gastric stromal tumor with dizziness as the main complaint: A case report and literature review
    Dongdong Zhang, Shuk Ying WONG, Jixiang Wu, Limin Guo
    International Journal of Surgery Case Reports.2023; 110: 108747.     CrossRef
  • Survival outcome of local versus radical resection for jejunoileal gastrointestinal stromal tumors: a propensity score-matched population-based analysis
    Shangcheng Yan, Wei Peng, Ming Cheng, Jingyu Zhang, Tianhua Liu, Mengchao Sheng, Rui Ren, Qiang Chen, Wei Gong, Yongyou Wu
    International Journal of Colorectal Disease.2023;[Epub]     CrossRef
  • CT features of calcified micro-gastric gastrointestinal stromal tumors: a case series
    Li-Jun Chen, Yue-Dong Han, Ming Zhang
    BMC Medical Imaging.2023;[Epub]     CrossRef
  • Rapidly Growing, High-Risk Gastrointestinal Stromal Tumor of the Stomach: A Case Report
    Sung Jin Lim, Han Mo Yoo, Seung-Woo Lee, Hae Joung Sul, Dong Soo Lee
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2023; 23(4): 306.     CrossRef
  • Factors associated with gastrointestinal stromal tumor rupture and pathological risk: A single-center retrospective study
    Jia-Zheng Liu, Zhong-Wen Jia, Ling-Ling Sun
    World Journal of Radiology.2023; 15(12): 350.     CrossRef
  • Clinical outcomes of endoscopic resection for the treatment of gastric gastrointestinal stromal tumors originating from the muscularis propria: a 7-year experience from a large tertiary center in China
    Chen Du, Ningli Chai, Enqiang Linghu, Huikai Li, Yaqi Zhai, Longsong Li, Xiaowei Tang, Hongbin Wang, Ping Tang
    Surgical Endoscopy.2022; 36(2): 1544.     CrossRef
  • Radiomics Nomogram Based on Contrast-enhanced CT to Predict the Malignant Potential of Gastrointestinal Stromal Tumor: A Two-center Study
    Yancheng Song, Jie Li, Hexiang Wang, Bo Liu, Chentong Yuan, Hao Liu, Ziwen Zheng, Fanyi Min, Yu Li
    Academic Radiology.2022; 29(6): 806.     CrossRef
  • Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors
    Keiko Maekawa, Masahiro Yamamura, Atsushi Matsuki, Takashi Ishikawa, Toshihiro Hirai, Yoshiyuki Yamaguchi, Yoshiro Saito, Tatsuo Kanda
    Drug Metabolism and Pharmacokinetics.2022; 43: 100441.     CrossRef
  • Clinical Course of Small Subepithelial Tumors of the Small Bowel Detected on CT
    Seohyun Kim, Seung Joon Choi, Su Joa Ahn, So Hyun Park, Young Sup Shim, Jeong Ho Kim
    Journal of the Korean Society of Radiology.2022; 83(3): 608.     CrossRef
  • Clinical outcomes of endoscopic treatment for gastric gastrointestinal stromal tumors: a single-center study of 240 cases in China
    Deqiong Wang, Qiang Ding, Li Cao, Xinxia Feng, Zerui Zhang, Panpan Lu, Xiaoyu Ji, Lili Li, Dean Tian, Mei Liu
    Scandinavian Journal of Gastroenterology.2022; 57(8): 996.     CrossRef
  • The Diagnosis of Small Gastrointestinal Subepithelial Lesions by Endoscopic Ultrasound-Guided Fine Needle Aspiration and Biopsy
    Masanari Sekine, Takeharu Asano, Hirosato Mashima
    Diagnostics.2022; 12(4): 810.     CrossRef
  • A Huge Malignant Gastric Gastrointestinal Stromal Tumor in a Young Patient
    Yun Jin Jeong, Hyun Seung Hwang, Yong Eun Park, Kyung Han Nam, Sung Jin Oh
    The Korean Journal of Gastroenterology.2022; 79(4): 177.     CrossRef
  • Advancements in the Diagnosis of Gastric Subepithelial Tumors
    Osamu Goto, Mitsuru Kaise, Katsuhiko Iwakiri
    Gut and Liver.2022; 16(3): 321.     CrossRef
  • Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis
    Sora Kang, Min-Hee Ryu, Yeong Hak Bang, Hyung-Don Kim, Hyung Eun Lee, Yoon-Koo Kang
    Cancer Research and Treatment.2022; 54(4): 1167.     CrossRef
  • The analysis of prognostic factors of primary small intestinal gastrointestinal stromal tumors with R0 resection
    Hui Qu, ZhaoHui Xu, YanYing Ren, ZeZhong Gong, Ri Hyok Ju, Fan Zhang, Shuai Shao, XiaoLiang Chen, Xin Chen
    Medicine.2022; 101(25): e29487.     CrossRef
  • Clinical outcomes and prognostic factors for patients with high‐risk gastrointestinal stromal tumors treated with 3‐year adjuvant imatinib
    Yeong Hak Bang, Min‐Hee Ryu, Hyung‐Don Kim, Hyung Eun Lee, Yoon‐Koo Kang
    International Journal of Cancer.2022; 151(10): 1770.     CrossRef
  • Prognostic significance of hemoglobin, albumin, lymphocyte, platelet in gastrointestinal stromal tumors: A propensity matched retrospective cohort study
    Zhou Zhao, Xiao-Nan Yin, Jian Wang, Xin Chen, Zhao-Lun Cai, Bo Zhang
    World Journal of Gastroenterology.2022; 28(27): 3476.     CrossRef
  • Therapeutic Effects of 4 Surgical Approaches for Small Gastrointestinal Stromal Tumors: A Network Meta-analysis
    Zhiyuan Yu, Huaiyu Tu, Chen Liang, Shuzhong Qiu, Xiaoyu Dong, Yonghui Zhang, Chao Ma, Peiyu Li
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2022;[Epub]     CrossRef
  • Necessity of Individualized Approach for Gastric Subepithelial Tumor Considering Pathologic Discrepancy and Surgical Difficulty Depending on the Gastric Location
    Sung Gon Kim, Bang Wool Eom, Hongman Yoon, Myeong-Cheorl Kook, Young-Woo Kim, Keun Won Ryu
    Journal of Clinical Medicine.2022; 11(16): 4733.     CrossRef
  • Laparoscopic versus open resection for the treatment of gastric GIST: a retrospective 10-year single-center experience
    Andrea LOCATELLI, Daniele CARZANIGA, Pierluigi CARZANIGA, Andrea COSTANZI
    Minerva Surgery.2022;[Epub]     CrossRef
  • Case report: 10-year survival of a patient with a primary hepatic gastrointestinal stromal tumor
    Jie Lian, Meiyan Feng, Shumei Zhang, Haibo Lu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Clinical outcomes of laparoscopic and endoscopic cooperative surgery for gastric gastrointestinal stromal tumor
    Hiroyuki Hanayama, Masanori Katagata, Takahiro Sato, Hiroshi Nakano, Takuro Matsumoto, Takeshi Tada, Yohei Watanabe, Suguru Hayase, Hirokazu Okayama, Tomoyuki Momma, Tsunetaka Kato, Minami Hashimoto, Jun Nakamura, Takuto Hikichi, Zenichiro Saze, Koji Kono
    FUKUSHIMA JOURNAL OF MEDICAL SCIENCE.2022; 68(3): 169.     CrossRef
  • Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan
    Yuichi Ichinose, Yi-Hsin Yang, Hui-Jen Tsai, Ru-Yu Huang, Takahiro Higashi, Toshirou Nishida, Li-Tzong Chen
    Scientific Reports.2022;[Epub]     CrossRef
  • Gastrointestinal stromal tumor of the small intestine of high malignant potential
    Aleksandar Mladenović, Miljan Jovančević, Zoran Milošević
    PONS - medicinski casopis.2022; 19(1): 33.     CrossRef
  • Development and validation of a novel diagnostic model for initially clinical diagnosed gastrointestinal stromal tumors using an extreme gradient-boosting machine
    Bozhi Hu, Chao Wang, Kewei Jiang, Zhanlong Shen, Xiaodong Yang, Mujun Yin, Bin Liang, Qiwei Xie, Yingjiang Ye, Zhidong Gao
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Incidence of gastrointestinal stromal tumor in Chinese urban population: A national population‐based study
    Lu Xu, Yanpeng Ma, Shengfeng Wang, Jingnan Feng, Lili Liu, Jinxi Wang, Guozhen Liu, Dianrong Xiu, Wei Fu, Siyan Zhan, Tao Sun, Pei Gao
    Cancer Medicine.2021; 10(2): 737.     CrossRef
  • Malignant solitary fibrous tumor of the greater omentum: A case report and review of literature
    Yu-Chen Guo, Li-Yu Yao, Zhi-Sen Tian, Bing Shi, Ying Liu, Yuan-Yi Wang
    World Journal of Clinical Cases.2021; 9(2): 445.     CrossRef
  • A Case of Liver Metastasis from Small Intestinal Gastrointestinal Stromal Tumor 25 Years after Surgery including Autopsy Findings
    Yuichi Takano, Masataka Yamawaki, Jun Noda, Tetsushi Azami, Takahiro Kobayashi, Fumitaka Niiya, Eiichi Yamamura, Naotaka Maruoka, Kuniyo Gomi, Yuichiro Kuroki, Yorimasa Yamamoto, Tomoko Norose, Nobuyuki Ohike, Masatsugu Nagahama, Marcel Cerqueira Cesar Ma
    Case Reports in Gastrointestinal Medicine.2021; 2021: 1.     CrossRef
  • Gastrointestinal stromal tumours
    Jean-Yves Blay, Yoon-Koo Kang, Toshiroo Nishida, Margaret von Mehren
    Nature Reviews Disease Primers.2021;[Epub]     CrossRef
  • A modified endoscopic full thickness resection for gastric subepithelial tumors from muscularis propria layer: Novel method
    Jung Min Lee, In Kyung Yoo, Sung Pyo Hong, Joo Young Cho, Young Kwan Cho
    Journal of Gastroenterology and Hepatology.2021; 36(9): 2558.     CrossRef
  • Recent Progress and Challenges in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors
    Toshirou Nishida, Shigetaka Yoshinaga, Tsuyoshi Takahashi, Yoichi Naito
    Cancers.2021; 13(13): 3158.     CrossRef
  • Diagnosis of gastric submucosal tumors and estimation of malignant risk of GIST by endoscopic ultrasound. Comparison between B mode and contrast-harmonic mode
    Christine Lefort, Vikas Gupta, Andrea Lisotti, Laurent Palazzo, Pietro Fusaroli, Bertrand Pujol, Rodica Gincul, Fabien Fumex, Maxime Palazzo, Bertrand Napoléon
    Digestive and Liver Disease.2021; 53(11): 1486.     CrossRef
  • Gastrointestinal Stromal Tumors—A Mini Review
    Gina Gheorghe, Nicolae Bacalbasa, Gabriela Ceobanu, Madalina Ilie, Valentin Enache, Gabriel Constantinescu, Simona Bungau, Camelia Cristina Diaconu
    Journal of Personalized Medicine.2021; 11(8): 694.     CrossRef
  • Controversies in EUS: Do we need miniprobes?
    Hans Seifert, Pietro Fusaroli, PaoloGiorgio Arcidiacono, Barbara Braden, Felix Herth, Michael Hocke, Alberto Larghi, Bertrand Napoleon, Mihai Rimbas, BogdanSilvio Ungureanu, Adrian Sãftoiu, AnandV Sahai, ChristophF Dietrich
    Endoscopic Ultrasound.2021; 10(4): 246.     CrossRef
  • Convolutional neural network‐based object detection model to identify gastrointestinal stromal tumors in endoscopic ultrasound images
    Chang Kyo Oh, Taewan Kim, Yu Kyung Cho, Dae Young Cheung, Bo‐In Lee, Young‐Seok Cho, Jin Il Kim, Myung‐Gyu Choi, Han Hee Lee, Seungchul Lee
    Journal of Gastroenterology and Hepatology.2021; 36(12): 3387.     CrossRef
  • The Value of Endoscopic Ultrasonography in the Endoscopic Resection of Gastrointestinal Stromal Tumors
    Jian-Wei Mi, Jia-Qi Wang, Jie Liu, Li-Xian Zhang, Hong-Wei Du, Dong-Qiang Zhao
    International Journal of General Medicine.2021; Volume 14: 5149.     CrossRef
  • Factors predicting technical difficulties during endoscopic submucosal excavation for gastric submucosal tumor
    Jia Liu, Yuyong Tan, Deliang Liu, Chenjie Li, Meixian Le, Hejun Zhou
    Journal of International Medical Research.2021;[Epub]     CrossRef
  • Endoscopic Resection of Gastrointestinal Stromal Tumor: Is It Safe?
    Moon Kyung Joo
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2021; 21(3): 180.     CrossRef
  • Endoscopic Resection for Gastric Subepithelial Tumor with Backup Laparoscopic Surgery: Description of a Single-Center Experience
    Wei-Jung Chang, Lien-Cheng Tsao, Hsu-Heng Yen, Chia-Wei Yang, Joseph Lin, Kuo-Hua Lin
    Journal of Clinical Medicine.2021; 10(19): 4423.     CrossRef
  • Successful Endoscopic Resection of a Rectal Gastrointestinal Stromal Tumor Larger Than 5 cm
    Seong Jung Kim, Yun Jung, Ran Hong, Jun Lee
    The Korean Journal of Gastroenterology.2021; 78(4): 235.     CrossRef
  • A Nomogram for Predicting Laparoscopic and Endoscopic Cooperative Surgery during the Endoscopic Resection of Subepithelial Tumors of the Upper Gastrointestinal Tract
    Shun-Wen Hsiao, Mei-Wen Chen, Chia-Wei Yang, Kuo-Hua Lin, Yang-Yuan Chen, Chew-Teng Kor, Siou-Ping Huang, Hsu-Heng Yen
    Diagnostics.2021; 11(11): 2160.     CrossRef
  • Building Radiomics Models Based on Triple-Phase CT Images Combining Clinical Features for Discriminating the Risk Rating in Gastrointestinal Stromal Tumors
    Meihua Shao, Zhongfeng Niu, Linyang He, Zhaoxing Fang, Jie He, Zongyu Xie, Guohua Cheng, Jian Wang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Gastrointestinal stromal tumor of the rectum resected by transanal total mesorectal excision after neoadjuvant imatinib treatment: A case report
    Takuya Yano, Masahiro Nakahara, Hiroshi Okuda, Toshihiko Nishidate, Ichiro Takemasa, Masahiko Fujimori, Hirofumi Nakatsuka, Hironobu Amano, Hideki Ohdan, Toshio Noriyuki
    Asian Journal of Endoscopic Surgery.2020; 13(4): 574.     CrossRef
  • Wedge gastrectomy: Robot-assisted with a hand-sewn repair versus a laparoscopic linear stapler technique for gastric subepithelial tumors
    Chairat Supsamutchai, Thitipong Setthalikhit, Chumpon Wilasrusmee, Pornraksa Ovartchaiyapong, Jakrapan Jirasiritham, Pattawia Choikrua, Pitichote Hiranyatheb
    Laparoscopic, Endoscopic and Robotic Surgery.2020; 3(1): 17.     CrossRef
  • Impact of l-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor
    Heejung Chae, Min-Hee Ryu, Jungeun Ma, Moyeol Beck, Yoon-Koo Kang
    Investigational New Drugs.2020; 38(2): 493.     CrossRef
  • Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors
    Jian Wang, Yuan Yin, Chaoyong Shen, Xiaonan Yin, Zhaolun Cai, Lin Pu, Wei Fu, Yaxuan Wang, Bo Zhang
    Medicine.2020; 99(9): e19275.     CrossRef
  • Multiple Intra-abdominal Leiomyosarcoma in a Single Patient
    Rajshekhar C. Jaka, N. Chandra Mouli, T. Ravi Kumar, Akshay V. Gokak
    Indian Journal of Surgical Oncology.2020; 11(S1): 63.     CrossRef
  • Development and validation of a nomogram based on CT images and 3D texture analysis for preoperative prediction of the malignant potential in gastrointestinal stromal tumors
    Caiyue Ren, Shengping Wang, Shengjian Zhang
    Cancer Imaging.2020;[Epub]     CrossRef
  • Gastrointestinal Stromal Tumors of the Small Intestine: Progress in Diagnosis and Treatment Research


    Fangxing Peng, Yao Liu
    Cancer Management and Research.2020; Volume 12: 3877.     CrossRef
  • Comparison of endoscopic versus laparoscopic resection for gastric gastrointestinal stromal tumors: A preliminary meta‐analysis
    Hanlong Zhu, Si Zhao, Ruonan Jiao, Jian Zhou, Chunmei Zhang, Lin Miao
    Journal of Gastroenterology and Hepatology.2020; 35(11): 1858.     CrossRef
  • Laparoscopy‑assisted endoscopic full‑thickness resection of upper gastrointestinal subepithelial tumors: A single‑center early experience
    Prasit Mahawongkajit, Pakkavuth Chanswangphuvana
    Molecular and Clinical Oncology.2020;[Epub]     CrossRef
  • Skin Metastasis of Gastrointestinal Stromal Tumors: A Case Series and Literature Review


    Peng Liu, Fengbo Tan, Heli Liu, Jie Ge, Sheng Liu, Tianxiang Lei, Xianhui Zhao
    Cancer Management and Research.2020; Volume 12: 7681.     CrossRef
  • Laparoscopic Transabdominal Dissection and Transection of the Distal Rectum Followed by Local Excision Through the Anus for Rectal Gastrointestinal Stromal Tumor
    Shin Emoto, Takashi Akiyoshi, Koji Fukata, Toshiya Nagasaki, Yosuke Fukunaga
    Diseases of the Colon & Rectum.2020; 63(11): e542.     CrossRef
  • Laparoscopic resectional oesophago-gastroplasty: a novel technique for minimally invasive treatment of large high gastric lesser curve GIST involving gastroesophageal junction
    Mang Yik Foo, Baldwin P M Yeung, Jeremy T H Tan
    Journal of Surgical Case Reports.2020;[Epub]     CrossRef
  • Clinical features of multiple gastrointestinal stromal tumors: A pooling analysis combined with evidence and gap map
    Chen Li, Ke-Lu Yang, Quan Wang, Jin-Hui Tian, Yang Li, Zhi-Dong Gao, Xiao-Dong Yang, Ying-Jiang Ye, Ke-Wei Jiang
    World Journal of Gastroenterology.2020; 26(47): 7550.     CrossRef
  • Application of NOTES combined with ESD for the treatment of an exogenous gastric stromal tumor: A case report and review of the literature
    Xiao-Bo Liu, Zi-Ye Gao, Sandeep Pandey, Bao-Zhen Shan, Ping Liu, Chuan-Tao Sun, Sheng-Bao Li, Shu Jin
    World Academy of Sciences Journal.2020;[Epub]     CrossRef
  • Laparoscopic versus open resection of gastrointestinal stromal tumors: survival outcomes from the NCDB
    Colette S. Inaba, Austin Dosch, Christina Y. Koh, Sarath Sujatha-Bhaskar, Marija Pejcinovska, Brian R. Smith, Ninh T. Nguyen
    Surgical Endoscopy.2019; 33(3): 923.     CrossRef
  • Gastric sub-epithelial tumors: identification of gastrointestinal stromal tumors using CT with a practical scoring method
    Ming Liu, Liheng Liu, Erhu Jin
    Gastric Cancer.2019; 22(4): 769.     CrossRef
  • Per oral endoscopic tumor (POET) resection for treatment of upper gastrointestinal subepithelial tumors
    Philip Wai Yan Chiu, Hon Chi Yip, Anthony Yuen Bun Teoh, Vivien Wai Yin Wong, Shannon Melissa Chan, Simon Kin Hung Wong, Enders Kwok Wai Ng
    Surgical Endoscopy.2019; 33(4): 1326.     CrossRef
  • Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience
    Jwa Hoon Kim, Min‐Hee Ryu, Changhoon Yoo, Heejung Chae, Hana Na, Moyoul Beck, Beom Su Kim, Moon‐Won Yoo, Jeong Hwan Yook, Byung Sik Kim, Ki‐Hun Kim, Chan Wook Kim, Yoon‐Koo Kang
    Cancer Medicine.2019; 8(3): 1034.     CrossRef
  • PRE-OPERATIVE GASTRIC GIST DOWNSIZING: THE IMPORTANCE OF NEOADJUVANT THERAPY
    João Bernardo Sancio Rocha RODRIGUES, Renato Gomes CAMPANATI, Francisco NOLASCO, Athos Miranda BERNARDES, Soraya Rodrigues de Almeida SANCHES, Paulo Roberto SAVASSI-ROCHA
    ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo).2019;[Epub]     CrossRef
  • Value of contrast‐enhanced harmonic endoscopic ultrasonography in differentiating between gastrointestinal stromal tumors: A meta‐analysis
    Jia Yue Tang, Ke Gong Tao, Li Yuan Zhang, Kai Ming Wu, Jian Shi, Xin Zeng, Yong Lin
    Journal of Digestive Diseases.2019; 20(3): 127.     CrossRef
  • Future of full thickness resection – Devices, indications, robotics, what is missing
    Philip WY Chiu
    Techniques in Gastrointestinal Endoscopy.2019; 21(1): 48.     CrossRef
  • Clinicopathological Features and Prognosis of Small Gastric Gastrointestinal Stromal Tumors (GISTs)
    Mincong Wang, Anwei Xue, Wei Yuan, Xiaodong Gao, Min Fu, Yong Fang, Li Wang, Ping Shu, He Li, Yingyong Hou, Kuntang Shen, Yinghong Sun, Xinyu Qin
    Journal of Gastrointestinal Surgery.2019; 23(11): 2136.     CrossRef
  • Intra-abdominal desmoid tumors mimicking gastrointestinal stromal tumors —8 cases: A case report
    Jwa Hoon Kim, Min-Hee Ryu, Young Soo Park, Hyun Jin Kim, Hyojung Park, Yoon-Koo Kang
    World Journal of Gastroenterology.2019; 25(16): 2010.     CrossRef
  • Primary hepatic gastrointestinal stromal tumor with right adrenal gland invasion
    Liangliang Xu, Ming Zhang, Mingqing Xu
    Medicine.2019; 98(20): e15482.     CrossRef
  • Endoscopic full-thickness resection for a gastrointestinal stromal tumor in a liver transplant recipient
    Man Xie, Wei Rao, Peng Zhang, Qingxi Zhao, Zibin Tian
    Medicine.2019; 98(31): e16669.     CrossRef
  • Association of Hepatic Nuclear Factor 4 Alpha Gene Polymorphisms With Free Imatinib Plasma Levels and Adverse Reactions in Chinese Gastrointestinal Stromal Tumor Patients
    Hanmei Chen, Jing Liu, Yuhong Zhou, Yingyong Hou, Guo Ma, Weimin Cai
    Therapeutic Drug Monitoring.2019; 41(5): 582.     CrossRef
  • Value of CT-Based Texture Analysis in Preoperative Prediction of the Grade of Gastrointestinal Stromal Tumors Compared to Conventional CT Imaging
    Caiyue Ren, Shengping Wang, Shengjian Zhang, Zhaoxia Jiang
    Iranian Journal of Radiology.2019;[Epub]     CrossRef
  • Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy with Imatinib (Case Report)
    Fousséni Alassani, Boyodi Tchangai, Aklesso Bagny, Ablavi A. Adani-Ife, Kossigan A. Amavi, Tchin Darre, Komla Attipou
    Oncology and Therapy.2019; 7(2): 159.     CrossRef
  • Clinical Relevance of the Location of Gastric Gastrointestinal Stromal Tumors
    Eun Jeong Gong
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2019; 19(3): 143.     CrossRef
  • Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses
    Hyungwoo Cho, Min-Hee Ryu, Yongjune Lee, Young Soo Park, Ki-Hun Kim, Jwa Hoon Kim, Yangsoon Park, Sun Mi Lee, Chan Wook Kim, Beom Soo Kim, Moon-Won Yoo, Yoon-Koo Kang
    The Oncologist.2019; 24(12): e1443.     CrossRef
  • Gastrointestinal stromal tumors: Do we follow the current guidelines? A self-critique
    MohammadEzzedien Rabie, Abdelelah Hummadi, Mohammad Bazeed, Ismail El Hakeem, AbdullaSaad Al Qahtani, Hesham Haroon, Abbas Al Zain
    Saudi Surgical Journal.2019; 7(3): 100.     CrossRef
  • Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib
    Jae-Joon Kim, Min-Hee Ryu, Changhoon Yoo, Mo Youl Beck, Jung Eun Ma, Yoon-Koo Kang
    The Oncologist.2019; 24(11): e1212.     CrossRef
  • The fourth space surgery: endoscopic subserosal dissection for upper gastrointestinal subepithelial tumors originating from the muscularis propria layer
    Fei Liu, Song Zhang, Wei Ren, Tian Yang, Ying Lv, Tingsheng Ling, Xiaoping Zou, Lei Wang
    Surgical Endoscopy.2018; 32(5): 2575.     CrossRef
  • Robotic Gastrotomy With Intracorporeal Suture for Patients With Gastric Gastrointestinal Stromal Tumors Located at Cardia and Subcardiac Region
    Jian Zhao, Gang Wang, Zhiwei Jiang, Chuanwei Jiang, Jiang Liu, Jiahui Zhou, Jieshou Li
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2018; 28(1): e1.     CrossRef
  • Subepitheliale Raumforderungen
    N. Glaser, R. Thimme, A. Schmidt
    Der Gastroenterologe.2018; 13(2): 113.     CrossRef
  • Tyrosine kinase inhibitor therapies for gastrointestinal stromal tumours
    Simone Mocellin, Sandro Pasquali, Luca Campana, Yuhong Yuan, Alessandro Gronchi, Ewen Griffiths, Ravinder Vohra
    Cochrane Database of Systematic Reviews.2018;[Epub]     CrossRef
  • Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib
    Jianwei Tang, Rui Zhao, Xiaobo Zheng, Liangliang Xu, Yong Wang, Lei Feng, Shengsheng Ren, Peng Wang, Ming Zhang, Mingqing Xu
    Medicine.2018; 97(29): e11400.     CrossRef
  • A Novel Pathological Prognostic Score (PPS) to Identify “Very High-Risk” Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)
    Xuechao Liu, Haibo Qiu, Zhiming Wu, Peng Zhang, Xingyu Feng, Tao Chen, Yong Li, Kaixiong Tao, Guoxin Li, Xiaowei Sun, Zhiwei Zhou
    Journal of Gastrointestinal Surgery.2018; 22(12): 2150.     CrossRef
  • Inhibition of stromal‐interacting molecule 1‐mediated store‐operated Ca2+ entry as a novel strategy for the treatment of acquired imatinib‐resistant gastrointestinal stromal tumors
    Ziyi Yang, Lijia Pan, Shilei Liu, Fengnan Li, Wenjie Lv, Yijun Shu, Ping Dong
    Cancer Science.2018; 109(9): 2792.     CrossRef
  • Standard Approach to Gastrointestinal Stromal Tumors - Differences between China and Europe
    Lin Tu, Peter Hohenberger, Heike Allgayer, Hui Cao
    Visceral Medicine.2018; 34(5): 353.     CrossRef
  • Gastric ectopic pancreas mimicking a gastrointestinal stromal tumour: A case report
    Zdravko Štor, Jurij Hanžel
    International Journal of Surgery Case Reports.2018; 53: 348.     CrossRef
  • Tumor rupture of gastric gastrointestinal stromal tumors during endoscopic resection: a risk factor for peritoneal metastasis?
    Shiyi Song, Wei Ren, Yi Wang, Shu Zhang, Song Zhang, Fei Liu, Qiang Cai, Guifang Xu, Xiaoping Zou, Lei Wang
    Endoscopy International Open.2018; 06(08): E950.     CrossRef
  • Drill needle aspiration biopsy for submucosal tumors in an experimental study
    Masaya Uesato, Tomohide Tamachi, Naoyuki Hanari, Yorihiko Muto, Akiko Kagaya, Ryuma Urahama, Yukiko Ogura, Hiroshi Suito, Akira Nakano, Mizuho Aikawa, Takashi Oide, Hisahiro Matsubara
    Gastric Cancer.2017; 20(3): 475.     CrossRef
  • Tumor del estroma extragastrointestinal primario hepático gigante
    Ana María Carrillo Colmenero, Mario Serradilla Martín, Manuel de Dios Redondo Olmedilla, Francisco Manuel Ramos Pleguezuelos, Pedro López Leiva
    Cirugía Española.2017; 95(9): 547.     CrossRef
  • Cancer biology of small gastrointestinal stromal tumors (<2 cm): What is the risk of malignancy?
    K. Søreide
    European Journal of Surgical Oncology (EJSO).2017; 43(7): 1344.     CrossRef
  • An unexpected cause of gastric submucosal lesion
    Rachid Guimarães Nagem
    Einstein (São Paulo).2017; 15(1): 112.     CrossRef
  • Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST)
    Mónica Ballesteros, Nadia Montero, Antonio López-Pousa, Gerard Urrútia, Ivan Solà, Gabriel Rada, Hector Pardo-Hernandez, Xavier Bonfill
    BMC Medical Research Methodology.2017;[Epub]     CrossRef
  • Laparoscopic management of gastric gastrointestinal stromal tumors: A retrospective 10-year single-center experience
    Guan-Qun Liao, Tao Chen, Xiao-Long Qi, Yan-Feng Hu, Hao Liu, Jiang Yu, Guo-Xin Li
    World Journal of Gastroenterology.2017; 23(19): 3522.     CrossRef
  • Current research and treatment for gastrointestinal stromal tumors
    Kheng Tian Lim, Kok Yang Tan
    World Journal of Gastroenterology.2017; 23(27): 4856.     CrossRef
  • Involvement of Bmi-1 gene in the development of gastrointestinal stromal tumor by regulating p16 Ink4A /p14 ARF gene expressions: An in vivo and in vitro study
    Jiang-Li Wang, Jiang-Hong Wu, Cai Hong, Ya-Nong Wang, Ye Zhou, Zi-Wen Long, Ying Zhou, Hai-Shu Qin
    Pathology - Research and Practice.2017; 213(12): 1542.     CrossRef
  • Giant Primary Extra Gastrointestinal Stromal Tumor of the Liver
    Ana María Carrillo Colmenero, Mario Serradilla Martín, Manuel de Dios Redondo Olmedilla, Francisco Manuel Ramos Pleguezuelos, Pedro López Leiva
    Cirugía Española (English Edition).2017; 95(9): 547.     CrossRef
  • Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study
    Rui Zhao, Yong Wang, Yuqian Huang, Yaping Cui, Lin Xia, Yi Chen, Wen Zhuang, Yong Zhou, Xiaoting Wu
    Scientific Reports.2017;[Epub]     CrossRef
  • 25,979 View
  • 1,153 Download
  • 148 Web of Science
  • 133 Crossref
Close layer
Review Article
Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
Yoon-Koo Kang, Hye Jin Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
Cancer Res Treat. 2012;44(2):85-96.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.85
AbstractAbstract PDFPubReaderePub
Despite their rarity in incidence and prevalence, gastrointestinal stromal tumors (GISTs) have emerged as a distinct and noteworthy pathogenetic entity. The clinical management of GISTs has rapidly evolved due to the recent elucidation of their oncogenic signal transduction pathway and the introduction of molecular-targeted therapies. Successful management of GISTs requires a multidisciplinary approach firmly based on an accurate histopathologic diagnosis. In 2007, the Korean GIST study group published the first guideline for optimal diagnosis and treatment of GISTs in Korea. The second version of the guideline was published in 2010. Herein, we provide the results of relevant clinical studies for the purpose of further revision to the guideline. We expect this new guideline will enhance the accuracy of diagnosis, as performed by members of the Korean associate of physicians involved in GIST patient care, thus improving the efficacy of treatment.

Citations

Citations to this article as recorded by  
  • Diagnostic and Therapeutic Challenges in the Management of Acute Massive Overt Bleeding of Jejunal Gastrointestinal Stromal Tumours: Case Series
    Satish Subbiah Nagaraj, Sriram Deivasigamani, Amresh Aruni, Hemanth Kumar, Anurag Sachan, Jayanta Samanta, Amanjit Bal
    Journal of Gastrointestinal Cancer.2023; 54(1): 316.     CrossRef
  • The Feasibility and Safety of the Clip-and-Snare Method with a Prelooping Technique for Gastric Submucosal Tumors Removal: A Single-Center Experience (with Video)
    Qi Tang, Rui-Yue Shi, Jun Yao, Li-Sheng Wang, De-Feng Li, Alessandro Granito
    Canadian Journal of Gastroenterology and Hepatology.2022; 2022: 1.     CrossRef
  • Gastrointestinal stromal tumor of the small intestine of high malignant potential
    Aleksandar Mladenović, Miljan Jovančević, Zoran Milošević
    PONS - medicinski casopis.2022; 19(1): 33.     CrossRef
  • Rare Occurrence of Microsatellite Instability in Gastrointestinal Stromal Tumors
    Joonhong Park, Hae Jung Sul, Jeong Goo Kim
    Medicina.2021; 57(2): 174.     CrossRef
  • The Pathologic Confirmation in Subepithelial Tumors
    Kwan Hong Lee, Chan Kyoo Yoo, Hang Lak Lee, Kang Nyeong Lee, Dae Won Jun, Oh Young Lee, Dong Soo Han, Byung Chul Yoon, Ho Soon Choi, Jai Hoon Yoon
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2021; 21(3): 215.     CrossRef
  • Diagnosis and Treatment of Duodenal Gastrointestinal Stromal Tumors
    Haojie Du, Longgui Ning, Sha Li, Xinhe Lou, Hongtan Chen, Fengling Hu, Guodong Shan, Fenming Zhang, Guoqiang Xu
    Clinical and Translational Gastroenterology.2020; 11(3): e00156.     CrossRef
  • Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
    Hans Gelderblom, Robin L. Jones, Suzanne George, Claudia Valverde Morales, Charlotte Benson, Jean-Yves Blay, Daniel J. Renouf, Toshihiko Doi, Axel Le Cesne, Michael Leahy, Sabine Hertle, Paola Aimone, Ulrike Brandt, Patrick Schӧffski
    British Journal of Cancer.2020; 122(8): 1158.     CrossRef
  • Life-threatening bleeding with intussusception due to gastrointestinal stromal tumor: a case report
    Min Sung Kim, In Teak Woo, Young Min Jo, Jin Hyung Lee, Byung Sam Park
    Surgical Case Reports.2019;[Epub]     CrossRef
  • Safety profile and oncological outcomes of gastric gastrointestinal stromal tumors (GISTs) robotic resection: Single center experience
    Cristina Maggioni, Atsuo Shida, Raffaello Mancini, Luigi Ioni, Graziano Pernazza
    The International Journal of Medical Robotics and Computer Assisted Surgery.2019;[Epub]     CrossRef
  • A novel technique for removing large gastric subepithelial tumors with ESD method in the subcardia region
    Bingtuan Liu, Han Chen, Weifeng Zhang, Guoxin Zhang
    Oncology Letters.2019;[Epub]     CrossRef
  • Ultrasound-Guided Intraoperative Radiofrequency Ablation and Surgical Resection for Liver Metastasis from Malignant Gastrointestinal Stromal Tumors
    In Sun Yoon, Ji Hoon Shin, Kichang Han, Pyo Nyun Kim, Ki Hun Kim, Yoon-Koo Kang, Heung Kyu Ko
    Korean Journal of Radiology.2018; 19(1): 54.     CrossRef
  • Robotic Gastrotomy With Intracorporeal Suture for Patients With Gastric Gastrointestinal Stromal Tumors Located at Cardia and Subcardiac Region
    Jian Zhao, Gang Wang, Zhiwei Jiang, Chuanwei Jiang, Jiang Liu, Jiahui Zhou, Jieshou Li
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2018; 28(1): e1.     CrossRef
  • A Novel Pathological Prognostic Score (PPS) to Identify “Very High-Risk” Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)
    Xuechao Liu, Haibo Qiu, Zhiming Wu, Peng Zhang, Xingyu Feng, Tao Chen, Yong Li, Kaixiong Tao, Guoxin Li, Xiaowei Sun, Zhiwei Zhou
    Journal of Gastrointestinal Surgery.2018; 22(12): 2150.     CrossRef
  • Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
    Bruno Vincenzi, Margherita Nannini, Giuseppe Badalamenti, Giovanni Grignani, Elena Fumagalli, Silvia Gasperoni, Lorenzo D’Ambrosio, Lorena Incorvaia, Marco Stellato, Mariella Spalato Ceruso, Andrea Napolitano, Sergio Valeri, Daniele Santini, Giuseppe Toni
    Therapeutic Advances in Medical Oncology.2018;[Epub]     CrossRef
  • Current research and treatment for gastrointestinal stromal tumors
    Kheng Tian Lim, Kok Yang Tan
    World Journal of Gastroenterology.2017; 23(27): 4856.     CrossRef
  • Extra-gastrointestinal stromal tumor of the pancreas: report of a case
    Hyung Jun Kwon
    Annals of Hepato-Biliary-Pancreatic Surgery.2017; 21(4): 237.     CrossRef
  • The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines
    Toshirou Nishida, Jean-Yves Blay, Seiichi Hirota, Yuko Kitagawa, Yoon-Koo Kang
    Gastric Cancer.2016; 19(1): 3.     CrossRef
  • Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
    Sook Ryun Park, Min-Hee Ryu, Baek-Yeol Ryoo, Mo Youl Beck, In Soon Lee, Mi Jung Choi, Mi Woo Lee, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(1): 162.     CrossRef
  • Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors
    Changhoon Yoo, Min-Hee Ryu, Jungmin Jo, Inkeun Park, Baek-Yeol Ryoo, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(2): 546.     CrossRef
  • Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT)
    Changhoon Yoo, Min-Hee Ryu, Byung-Ho Nam, Baek-Yeol Ryoo, George D. Demetri, Yoon-Koo Kang
    European Journal of Cancer.2016; 52: 201.     CrossRef
  • Schwannoma of the stomach: a case report
    Aminder Singh, Ankur Mittal, Bhavna Garg, Neena Sood
    Journal of Medical Case Reports.2016;[Epub]     CrossRef
  • Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
    Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, Han-Kwang Yang, Akira Sawaki, Seiichi Hirota, Jie Zheng, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Toshirou Nishida, Lin Shen, Li-Tzong Chen, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(4): 1155.     CrossRef
  • Unusual gastroduodenal intussusception secondary to a gastrointestinal stromal tumor of the gastric fundus
    Toshihide Komatsubara, Toru Zuiki, Alan Kawarai Lefor, Norio Hirota, Jun Oki
    International Journal of Surgery Open.2016; 5: 33.     CrossRef
  • Rechallenge with imatinib in advanced gastrointestinal stromal tumors: clinical implications of the RIGHT trial
    Changhoon Yoo, Yoon-Koo Kang
    Clinical Investigation.2015; 5(7): 665.     CrossRef
  • The Role of Surgical Resection Following Imatinib Treatment in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses
    Seong Joon Park, Min-Hee Ryu, Baek-Yeol Ryoo, Young Soo Park, Byeong Seok Sohn, Hwa Jung Kim, Chan Wook Kim, Ki-Hun Kim, Chang Sik Yu, Jeong Hwan Yook, Byung Sik Kim, Yoon-Koo Kang
    Annals of Surgical Oncology.2014; 21(13): 4211.     CrossRef
  • Minimally invasive surgery for submucosal (subepithelial) tumors of the stomach
    Chang Min Lee
    World Journal of Gastroenterology.2014; 20(36): 13035.     CrossRef
  • Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
    Y-K Kang, C Yoo, B-Y Ryoo, J J Lee, E Tan, I Park, J H Park, Y J Choi, J Jo, J-S Ryu, M-H Ryu
    British Journal of Cancer.2013; 109(9): 2309.     CrossRef
  • Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
    Yoon-Koo Kang, Min-Hee Ryu, Changhoon Yoo, Baek-Yeol Ryoo, Hyun Jin Kim, Jong Jin Lee, Byung-Ho Nam, Nikhil Ramaiya, Jyothi Jagannathan, George D Demetri
    The Lancet Oncology.2013; 14(12): 1175.     CrossRef
  • Surgeon's role for gastric gastrointestinal stromal tumor in imatinib era
    Ji Yeon Park, Young-Woo Kim
    Korean Journal of Clinical Oncology.2013; 9(1): 5.     CrossRef
  • Diagnosis and Treatment of Gastrointestinal Stromal Tumor
    Yoon-Koo Kang, Dong Hoe Koo
    Korean Journal of Medicine.2013; 85(4): 341.     CrossRef
  • Surgical Treatment of Gastric Gastrointestinal Stromal Tumor
    Seong-Ho Kong, Han-Kwang Yang
    Journal of Gastric Cancer.2013; 13(1): 3.     CrossRef
  • Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan
    Chun-Nan Yeh, Tsann-Long Hwang, Ching-Shui Huang, Po-Huang Lee, Chew-Wun Wu, Ker Chen-Guo, Yi-Yin Jan, Miin-Fu Chen
    World Journal of Surgical Oncology.2012;[Epub]     CrossRef
  • 51,271 View
  • 133 Download
  • 32 Crossref
Close layer
Original Article
Effect on Cell Cycle Progression by N-Myc Knockdown in SK-N-BE(2) Neuroblastoma Cell Line and Cytotoxicity with STI-571 Compound
Un-Young Yu, Je-Eun Cha, Sun-Young Ju, Kyung-Ah Cho, Eun-Sun Yoo, Kyung-Ha Ryu, So-Youn Woo
Cancer Res Treat. 2008;40(1):27-32.   Published online March 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.1.27
AbstractAbstract PDFPubReaderePub
Purpose

Neuroblastoma is a common tumor in childhood, and generally exhibits heterogeneity and a malignant progression. MYCN expression and amplification profiles frequently correlate with therapeutic prognosis. Although it has been reported that MYCN silencing causes differentiation and apoptosis in human neuroblastoma cells, MYCN expression influences the cytotoxic potential of chemotherapeutic drugs via the deregulation of the cell cycle. STI-571 may constitute a promising therapeutic agent against neuroblastoma, particularly in cases in which c-Kit is expressed preferentially in MYCN-amplified neuroblastoma.

Materials and Methods

To determine whether STI-571 exerts a synergistic effect on cytotoxicity with MYCN expression, we assessed apoptotic cell death and cell cycle distribution after 72 h of exposure to STI-571 with or with out treatment of SK-N-BE(2) neuroblastoma cells with MYCN siRNA.

Results

MYCN siRNA-treated SK-N-BE(2) cells did not affect apoptosis and cells were arrested in G0/G1 phase after STI-571 treatment.

Conclusions

siRNA therapy targeted to MYCN may not be effective when administered in combination with STI-571 treatment in cases of neuroblastoma. Therefore, chemotherapeutic drugs that target S or G2-M phase may prove ineffective when applied to cells arrested in the G0/1 phase as the result of MYCN knockdown and STI-571 treatment.

Citations

Citations to this article as recorded by  
  • Subtype of Neuroblastoma Cells with High KIT Expression Are Dependent on KIT and Its Knockdown Induces Compensatory Activation of Pro-Survival Signaling
    Timofey Lebedev, Anton Buzdin, Elmira Khabusheva, Pavel Spirin, Maria Suntsova, Maxim Sorokin, Vladimir Popenko, Petr Rubtsov, Vladimir Prassolov
    International Journal of Molecular Sciences.2022; 23(14): 7724.     CrossRef
  • The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells
    Long Gu, Peiguo Chu, Robert Lingeman, Heather McDaniel, Steven Kechichian, Robert J. Hickey, Zheng Liu, Yate-Ching Yuan, John A. Sandoval, Gregg B. Fields, Linda H. Malkas
    EBioMedicine.2015; 2(12): 1923.     CrossRef
  • Comparative analysis of gene expression: Targeted antitumor therapy in neuroblastoma cell lines
    T. D. Lebedev, P. V. Spirin, N. N. Orlova, M. M. Prokofjeva, V. S. Prassolov
    Molecular Biology.2015; 49(6): 939.     CrossRef
  • A PCNA-Derived Cell Permeable Peptide Selectively Inhibits Neuroblastoma Cell Growth
    Long Gu, Shanna Smith, Caroline Li, Robert J. Hickey, Jeremy M. Stark, Gregg B. Fields, Walter H. Lang, John A. Sandoval, Linda H. Malkas, Anja-Katrin Bielinsky
    PLoS ONE.2014; 9(4): e94773.     CrossRef
  • SUMOylation of Myc-Family Proteins
    Arianna Sabò, Mirko Doni, Bruno Amati, Ramin Massoumi
    PLoS ONE.2014; 9(3): e91072.     CrossRef
  • Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma
    Jørn R Henriksen, Bjørn Helge Haug, Jochen Buechner, Ellen Tømte, Cecilie Løkke, Trond Flaegstad, Christer Einvik
    BMC Developmental Biology.2011;[Epub]     CrossRef
  • 9,498 View
  • 67 Download
  • 6 Crossref
Close layer
Case Report
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach: Report of Three Cases
Ji Seon Oh, Jae-Lyun Lee, Mi-Jung Kim, Min-Hee Ryu, Heung Moon Chang, Tae Won Kim, Se Jin Jang, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Yoon-Koo Kang
Cancer Res Treat. 2006;38(3):178-183.   Published online June 30, 2006
DOI: https://doi.org/10.4143/crt.2006.38.3.178
AbstractAbstract PDFPubReaderePub

Neoadjuvant imatinib therapy used to treat locally advanced or metastatic gastrointestinal stromal tumors (GI ST) remains under active investigation. We studied three cases of locally advanced gastric GISTs treated with imatinib on a neoadjuvant basis, followed by a complete surgical resection. Three patients were diagnosed with locally advanced unresectable GIST of the stomach and were started on imatinib 400 mg/day. After the imatinib treatment, partial responses were achieved in all patients and the tumors were considered resectable. Surgical resection was done after 7, 11, and 8 months of imatinib therapy, respectively. In one case, a metastatic liver lesion was detected during the imatinib treatment using computed tomography scans, so the imatinib therapy was maintained for 11 months postoperatively. In the other two patients without distant metastasis, imatinib treatment was not restarted after surgery. Mutational analysis revealed a mutation in exon 11 of the c-kit gene in two patients, and wild-type c-kit and PDGFRA in one patient. During pathology review of all three cases, we noted several features common to imatinib treatment. There was no evidence of tumor recurrence in all three patients at respective follow-up visits of 22, 15, and 7 months. These results suggest that the neoadjuvant imatinib therapy is a potentially curative approach for selected patients with locally advanced GIST.

Citations

Citations to this article as recorded by  
  • Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
    Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, Han-Kwang Yang, Akira Sawaki, Seiichi Hirota, Jie Zheng, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Toshirou Nishida, Lin Shen, Li-Tzong Chen, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(4): 1155.     CrossRef
  • Correlation between Computed Tomography and Pathological Findings of Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate
    Ki Choon Sim, Beom Jin Park, Na Yeon Han, Deuk Jae Sung, Min Ju Kim, Sung Bum Cho, Hyun Kwon Ha, Hyoung Rae Kim
    Journal of the Korean Society of Radiology.2014; 71(5): 239.     CrossRef
  • Diagnosis and Treatment of Gastrointestinal Stromal Tumor
    Yoon-Koo Kang, Dong Hoe Koo
    Korean Journal of Medicine.2013; 85(4): 341.     CrossRef
  • Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
    Yoon-Koo Kang, Hye Jin Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
    Cancer Research and Treatment.2012; 44(2): 85.     CrossRef
  • Efficacy of Imatinib Mesylate Neoadjuvant Treatment for a Locally Advanced Rectal Gastrointestinal Stromal Tumor
    Kyu Jong Yoon, Nam Kyu Kim, Kang Young Lee, Byung Soh Min, Hyuk Hur, Jeonghyun Kang, Sarah Lee
    Journal of the Korean Society of Coloproctology.2011; 27(3): 147.     CrossRef
  • Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
    Yoon-Koo Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Hye Jin Kang, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
    Journal of Korean Medical Science.2010; 25(11): 1543.     CrossRef
  • Clinical Practice Guideline for Adequate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
    Yoon-Koo Kang
    Journal of the Korean Medical Association.2007; 50(9): 830.     CrossRef
  • 11,183 View
  • 86 Download
  • 7 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP